Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Niegisch

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Der Urologe. Ausg. A|October 21, 2010
[Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?]G Niegisch, A Koch, J Knievel, et al.
Der Urologe. Ausg. A|April 4, 2020
[Report from the 9th symposium of the German Association for Bladder Cancer Research]W A Schulz, M J Hoffmann, G Niegisch, et al.
Der Urologe. Ausg. A|December 1, 2021
[Imaging of oligometastatic disease in selected urologic cancers]S A Koerber, C A Fink, K Dendl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2010
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]P Albers, S-I Park, G Niegisch, et al.
Urologie (Heidelberg, Germany)|August 26, 2024
[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer]G Niegisch, C Bolenz, C Doehn, et al.
Abdominal Radiology (New York)|October 31, 2023
MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancerM Boschheidgen, L Schimmöller, R Kastl, et al.
Molecular Imaging and Biology|November 12, 2022
PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual ReproducibilityE Mamlins, D Schmitt, M Beu, et al.
Molecular Imaging and Biology|March 29, 2022
Head-to-head Intra-individual Comparison of [<sup>68</sup>Ga]-FAPI and [<sup>18</sup>F]-FDG PET/CT in Patients with Bladder CancerE Novruzov, K Dendl, H Ndlovu, et al.
Clinical Genitourinary Cancer|June 6, 2016
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial CarcinomaG Sonpavde, G R Pond, G Di Lorenzo, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Der Urologe. Ausg. A|October 21, 2010
[Signal transduction in urothelial cancer: how exactly do we know the targets for targeted therapy?]G Niegisch, A Koch, J Knievel, et al.
Der Urologe. Ausg. A|April 4, 2020
[Report from the 9th symposium of the German Association for Bladder Cancer Research]W A Schulz, M J Hoffmann, G Niegisch, et al.
Der Urologe. Ausg. A|December 1, 2021
[Imaging of oligometastatic disease in selected urologic cancers]S A Koerber, C A Fink, K Dendl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 5, 2010
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]P Albers, S-I Park, G Niegisch, et al.
Urologie (Heidelberg, Germany)|August 26, 2024
[German expert consensus on programmed cell death ligand 1 (PD-L1) testing in perioperative systemic therapy of muscle invasive bladder cancer]G Niegisch, C Bolenz, C Doehn, et al.
Abdominal Radiology (New York)|October 31, 2023
MRI characteristics and oncological follow-up of patients with ISUP grade group 4 or 5 prostate cancerM Boschheidgen, L Schimmöller, R Kastl, et al.
Molecular Imaging and Biology|November 12, 2022
PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual ReproducibilityE Mamlins, D Schmitt, M Beu, et al.
Molecular Imaging and Biology|March 29, 2022
Head-to-head Intra-individual Comparison of [<sup>68</sup>Ga]-FAPI and [<sup>18</sup>F]-FDG PET/CT in Patients with Bladder CancerE Novruzov, K Dendl, H Ndlovu, et al.
Clinical Genitourinary Cancer|June 6, 2016
Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial CarcinomaG Sonpavde, G R Pond, G Di Lorenzo, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Pageof 3